RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves
Hims may have an chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.
Hims may have an chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
